Herophilus Announces Results from Research Collaboration with Cerevel


Fascinating. We may see a cure within the next 20 years!

1 Like

hello, can you briefly write what is written there. I can’t open the site.

This collaboration is a great example of the commitment by a leading neuroscience company such as Cerevel to invest in cutting-edge approaches to develop potentially disease-modifying therapies for one of the most difficult and common brain diseases," said Saul Kato, PhD, CEO of Herophilus. “The C4A NICO™ model built as part of this research collaboration can now potentially be used for the discovery of novel compounds that may prevent or reverse schizophrenia in patients, or for the discovery of biomarkers that may help detect the disease and track its progression before psychiatric symptoms manifest in a patient.”